9Was It Worth It? Cost-Effectiveness in Adults
A cochlear implant is expensive, so payers ask whether the hearing it restores justifies the price. Cost-utility analysis converts hearing gain into quality-adjusted life years and divides cost by that gain. Across the landmark adult studies the verdict is consistent: unilateral implantation in postlingually deaf adults sits near the top of the value table, inside the thresholds payers use to fund care.
TThe currency: utility gain and the QALY
Cost-utility analysis converts outcomes into quality-adjusted life years (QALYs), computed as life expectancy multiplied by a health utility score anchored at 0.00 (death) and 1.00 (perfect health); the result is expressed as cost per QALY gained. Profound deafness in adulthood carries a mean health-utility decrement of about -0.46 on the 0-1 scale, with studies spanning -0.36 to -0.63; the Wyatt HUI study of deaf-unimplanted controls measured a loss of -0.41. Utility is elicited directly by visual analogue scale, time trade-off, or standard gamble, or read off population-tariffed instruments such as the Health Utilities Index Mark III, which uniquely contains hearing and speech attributes. Pooled across seven early adult studies (n=520) the mean health-utility gain after implantation is about +0.26 (95% CI +0.24 to +0.28), translating to roughly +0.26 QALYs per implanted adult.[2009][1996][1996][1999]
TThe landmark adult cost-utility studies
Wyatt and Niparko (1996) used the HUI cross-sectionally in profoundly deaf adults and quantified the deafness-related utility decrement that anchors every later estimate. Palmer and colleagues (1999) prospectively compared 46 implanted adults against 16 unimplanted controls and recorded a +0.20 utility gain over one year. The UK Cochlear Implant Study Group analysis (Summerfield) found the largest gains and best cost-utility in traditional candidates reaching ~50% open-set sentence recognition; earlier VAS work showed gains of +0.41 (VAS-without) and +0.23 (VAS-before). Cheng and Niparko's (1999) meta-analysis pooled the adult literature to a weighted-average cost-utility of about $12,847 per QALY, the single most-cited adult CI value.[1996][1999][1995][1999]
CThe cost-per-QALY range and where it sits
Across the landmark adult analyses cost-utility ratios span roughly $9,000 to $31,177 per QALY, with the pooled weighted average near $12,847 per QALY. These figures fall inside the willingness-to-pay thresholds payers use ($20,000-$50,000 per QALY in US practice), placing adult unilateral CI alongside coronary bypass and dialysis. In the UK the NICE threshold is about 20,000-30,000 GBP per QALY; UK candidates fall within this band, and traditional candidates reach about 10,000 GBP per QALY, underpinning NICE technology appraisal TA166. By WHO-CHOICE benchmarks of 1-3x GDP per capita, adult CI clears the bar in high-income settings, though the same $25,000-$100,000 device-and-surgery cost can exceed that many-fold in low-income countries.[1999][2009][2009][2021]
CWhat drives the utility gain, and what doesn't
Adult HUI3 utility gains after implantation cluster around +0.19 to +0.26, recovering roughly 26-50% of the deafness decrement; preoperative utility in postlingually deaf adults sits near 0.43-0.54. Generic preference-based instruments (SF-6D, EQ-5D, even HUI) detect benefit mainly through non-hearing domains such as role function, vitality, and social and emotional functioning, underestimating hearing-specific gain captured by NCIQ and CIQOL. Postlingual deafness, younger age, and shorter duration of deafness predict larger gains; implantation more than ~30 years after onset, or prelingual deafness, yields notably smaller gains. Music perception remains degraded after implantation despite restored speech understanding, a reminder that the utility figure averages domains that improve unevenly.[2009][2008][2019][2009]
Which single figure best supports funding by reference to the published adult cost-utility literature, and why is this patient a favorable case?
In the pooled adult cochlear-implant cost-utility literature, the most frequently cited weighted-average cost per QALY for unilateral implantation is approximately:
Why do generic preference-based instruments such as the HUI and EQ-5D tend to underestimate the benefit of cochlear implantation compared with disease-specific tools like the NCIQ or CIQOL?